We investigated the role of the kallikrein-kinin system in blood press
ure control by developing transgenic mice overexpressing human tissue
kallikrein. Two lines of transgenic mice carrying the human tissue kal
likrein gene under the control of the mouse metallothionein metal-resp
onsive promoter were established. Human tissue kallikrein was identifi
ed in pancreas, salivary gland, kidney, liver, and spleen of the trans
genic mice by a specific radioimmunoassay for human tissue kallikrein.
The immunoreactive human tissue kallikrein reached high levels in the
circulation. The linear displacement curves for the transgenic produc
t were parallel with the human tissue kallikrein standard curve, indic
ating their immunologic identity. The expression of human tissue kalli
krein transcript in the transgenic mice was further confirmed by North
ern blot analysis and by reverse transcription-polymerase chain reacti
on followed by Southern blot. Both lines of transgenic mice had signif
icantly lowered blood pressure (86.4+/-13.5 mm Hg [mean+/-SD], n=8 and
78.9+/-12.4 mm Hg, n=8) compared with control mice (100.9+/-5.0 mm Hg
, n=8). Induction with zinc did not lower the blood pressure further d
espite elevated expression of the transgene. Administration of aprotin
in, a potent tissue kallikrein inhibitor, restored the blood pressure
of the transgenic mice but had no significant effect on control litter
-mates. Our findings raise the possibility of tissue kallikrein being
a powerful modulator of blood pressure and provide a new animal model
for the study of blood pressure regulation.